Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research.

The collaboration leverages Tempus’ AI-powered data analytics platform, Lens, to analyze and restructure the Center’s repository of genomic data. Together, the Center and Tempus teams will work to uncover genomic patterns that have the potential to advance the understanding of Alzheimer’s disease, investigate the gene and cell types affected, enable the development of new therapeutics, and accelerate the creation of novel clinical applications. By harnessing Lens’ advanced AI capabilities, the collaboration aims to generate actionable insights that drive the discovery of targeted therapies and significantly improve patient outcomes.

“We are excited to collaborate with the Abrams Research Center on Neurogenomics to confront one of the most complex and pressing medical challenges of our time,” said Ryan Fukushima, Chief Operating Officer at Tempus. “By integrating our AI platform with the Center’s pioneering work in neurogenomics, we are opening new avenues for discovery. Together, we strive to advance research for Alzheimer’s and bring hope and tangible impact to patients and families affected by this devastating disease.”

“This collaboration with Tempus represents an important step forward in our mission to harness cutting-edge technologies to transform Alzheimer’s research,” said David Gate, PhD, assistant professor in Ken and Ruth Davee Department of Neurology at Feinberg and head of The Abrams Research Center on Neurogenomics. “We share a commitment to deepen our understanding of the genomic underpinnings of Alzheimer’s disease and accelerate the development of more targeted, effective interventions.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding the expected outcomes and benefits of the collaboration with the Abrams Research Center on Neurogenomics to advance research for Alzheimer’s disease are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.